Gait characterization in golden retriever muscular dystrophy dogs using linear discriminant analysis

BMC Musculoskeletal Disorders

Volumn 18, Issue 1, 2017, Pages

  Fraysse, Bodvaël ^a   Barthélémy, Inès ^b,c,d   Qannari, El Mostafa ^e   Rouger, Karl ^e   Thorin, Chantal ^e   Blot, Stéphane ^b,c,d   Le Guiner, Caroline ^a   Chérel, Yan ^e   Hogrel, Jean Yves ^f  

^a UNIVERSITÉ DE NANTES   (France)

^b APHP Hopital Henri Mondor   (France)

^c UNIVERSITÉ PARIS EST   (France)

^d FACULTÉ DE MÉDECINE   (France)

^e LUNAM UNIVERSITÉ   (France)

^f Institute of Myology   (France)

Author keywords

Accelerometry; Animal model; Discriminant analysis; Gait assessment; GRMD; Muscular dystrophy; Treatment evaluation

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT;

ACCELEROMETRY; AGE; ARTICLE; CLINICAL OUTCOME; CORRELATION ANALYSIS; DISCRIMINANT ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; GAIT; GENOTYPE; GOLDEN RETRIEVER; IMMUNOSUPPRESSIVE TREATMENT; LINEAR DISCRIMINANT ANALYSIS; MALE; MEASUREMENT ACCURACY; NONHUMAN; PHENOTYPE; PROBABILITY; ANIMAL; CLINICAL DECISION MAKING; DEVICES; DISEASE MODEL; DOG; DRUG EFFECTS; GENETICS; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VALIDATION STUDY;

ACCELEROMETRY; AGE FACTORS; ANIMALS; CLINICAL DECISION-MAKING; DISCRIMINANT ANALYSIS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOGS; GAIT; GENOTYPE; IMMUNOSUPPRESSIVE AGENTS; LINEAR MODELS; MALE; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; PHENOTYPE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 85018465228     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/s12891-017-1494-4     Document Type: Article

References (20)

1. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987;50(3):509-17.
2. Wein N, Alfano L, Flanigan KM. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy. Pediatr Clin North Am. 2015;62(3):723-42.
3. Sienkiewicz D, Kulak W, Okurowska-Zawada B, Paszko-Patej G, Kawnik K. Duchenne muscular dystrophy: current cell therapies. Ther Adv Neurol Disord. 2015;8(4):166-77.
4. Valentine BA, Winand NJ, Pradhan D, Moise NS, de Lahunta A, Kornegay JN, Cooper BJ. Canine X-linked muscular dystrophy as an animal model of Duchenne muscular dystrophy: a review. Am J Med Genet. 1992;42(3):352-6.
5. McGreevy JW, Hakim CH, McIntosh MA, Duan D. Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech. 2015;8(3):195-213.
6. Kornegay JN, Bogan JR, Bogan DJ, Childers MK, Li J, Nghiem P, Detwiler DA, Larsen CA, Grange RW, Bhavaraju-Sanka RK, et al. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome. 2012;23(1-2):85-108.
7. Willmann R, Possekel S, Dubach-Powell J, Meier T, Ruegg MA. Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul Disord. 2009;19(4):241-9.
8. Vieira NM, Guo LT, Estrela E, Kunkel LM, Zatz M, Shelton GD. Muscular dystrophy in a family of Labrador Retrievers with no muscle dystrophin and a mild phenotype. Neuromuscul Disord. 2015;25(5):363-70.
9. Zatz M, Pavanello RC, Lazar M, Yamamoto GL, Lourenco NC, Cerqueira A, Nogueira L, Vainzof M. Milder course in Duchenne patients with nonsense mutations and no muscle dystrophin. Neuromuscul Disord. 2014;24(11):986-9.
10. Barthelemy I, Barrey E, Aguilar P, Uriarte A, Le Chevoir M, Thibaud JL, Voit T, Blot S, Hogrel JY. Longitudinal ambulatory measurements of gait abnormality in dystrophin-deficient dogs. BMC Musculoskelet Disord. 2011;12:75.
11. Barthelemy I, Barrey E, Thibaud JL, Uriarte A, Voit T, Blot S, Hogrel JY. Gait analysis using accelerometry in dystrophin-deficient dogs. Neuromuscul Disord. 2009;19(11):788-96.
12. Barthelemy I, Uriarte A, Drougard C, Unterfinger Y, Thibaud JL, Blot S. Effects of an immunosuppressive treatment in the GRMD dog model of Duchenne muscular dystrophy. PLoS One. 2012;7(11), e48478.
13. Marsh AP, Eggebeen JD, Kornegay JN, Markert CD, Childers MK. Kinematics of gait in golden retriever muscular dystrophy. Neuromuscul Disord. 2010;20(1):16-20.
14. Shin JH, Greer B, Hakim CH, Zhou Z, Chung YC, Duan Y, He Z, Duan D. Quantitative phenotyping of Duchenne muscular dystrophy dogs by comprehensive gait analysis and overnight activity monitoring. PLoS One. 2013;8(3), e59875.
15. Bartlett RJ, Winand NJ, Secore SL, Singer JT, Fletcher S, Wilton S, Bogan DJ, Metcalf-Bogan JR, Bartlett WT, Howell JM, et al. Mutation segregation and rapid carrier detection of X-linked muscular dystrophy in dogs. Am J Vet Res. 1996;57(5):650-4.
16. Stewart S, Ivy MA, Anslyn EV. The use of principal component analysis and discriminant analysis in differential sensing routines. Chem Soc Rev. 2014;43(1):70-84.
17. Nathan R, Spiegel O, Fortmann-Roe S, Harel R, Wikelski M, Getz WM. Using tri-axial acceleration data to identify behavioral modes of free-ranging animals: general concepts and tools illustrated for griffon vultures. J Exp Biol. 2012;215(Pt 6):986-96.
18. Dell'Agnola C, Wang Z, Storb R, Tapscott SJ, Kuhr CS, Hauschka SD, Lee RS, Sale GE, Zellmer E, Gisburne S, et al. Hematopoietic stem cell transplantation does not restore dystrophin expression in Duchenne muscular dystrophy dogs. Blood. 2004;104(13):4311-8.
19. Sampaolesi M, Blot S, D'Antona G, Granger N, Tonlorenzi R, Innocenzi A, Mognol P, Thibaud JL, Galvez BG, Barthelemy I, et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature. 2006;444(7119):574-9.
20. Rouger K, Larcher T, Dubreil L, Deschamps JY, Le Guiner C, Jouvion G, Delorme B, Lieubeau B, Carlus M, Fornasari B, et al. Systemic delivery of allogenic muscle stem cells induces long-term muscle repair and clinical efficacy in duchenne muscular dystrophy dogs. Am J Pathol. 2011;179(5):2501-18.